ES2555279T3 - Neuroprotección en enfermedades desmielinizantes - Google Patents
Neuroprotección en enfermedades desmielinizantes Download PDFInfo
- Publication number
- ES2555279T3 ES2555279T3 ES11742896.1T ES11742896T ES2555279T3 ES 2555279 T3 ES2555279 T3 ES 2555279T3 ES 11742896 T ES11742896 T ES 11742896T ES 2555279 T3 ES2555279 T3 ES 2555279T3
- Authority
- ES
- Spain
- Prior art keywords
- dmf
- subject
- interferon beta
- administered
- combination therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US304325P | 2001-07-10 | ||
US30432510P | 2010-02-12 | 2010-02-12 | |
US32148610P | 2010-04-06 | 2010-04-06 | |
US321486P | 2010-04-06 | ||
PCT/US2011/024594 WO2011100589A1 (fr) | 2010-02-12 | 2011-02-11 | Neuroprotection dans les maladies démyélinisantes |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2555279T3 true ES2555279T3 (es) | 2015-12-30 |
Family
ID=44368163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11742896.1T Active ES2555279T3 (es) | 2010-02-12 | 2011-02-11 | Neuroprotección en enfermedades desmielinizantes |
Country Status (14)
Country | Link |
---|---|
US (3) | US20130287732A1 (fr) |
EP (2) | EP2533634B1 (fr) |
DK (1) | DK2533634T3 (fr) |
ES (1) | ES2555279T3 (fr) |
HK (1) | HK1179116A1 (fr) |
HR (1) | HRP20151350T1 (fr) |
HU (1) | HUE025878T2 (fr) |
ME (1) | ME02317B (fr) |
PL (1) | PL2533634T3 (fr) |
PT (1) | PT2533634E (fr) |
RS (1) | RS54551B1 (fr) |
SI (1) | SI2533634T1 (fr) |
SM (1) | SMT201600014B (fr) |
WO (1) | WO2011100589A1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0410805A (pt) | 2003-09-09 | 2006-06-27 | Fumapharm Ag | uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma |
DE14172398T1 (de) | 2004-10-08 | 2015-01-08 | Forward Pharma A/S | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
PT2653873T (pt) | 2007-02-08 | 2022-07-26 | Biogen Ma Inc | Composições e utilizações para o tratamento de esclerose múltipla |
SI2139467T1 (sl) * | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Zaščita živčevja pri demielinizacijskih obolenjih |
SI2564839T1 (sl) | 2009-01-09 | 2016-09-30 | Forward Pharma A/S | Farmacevtska formulacija, obsegajoča enega ali več estrov fumarne kisline v erozijskem ogrodju |
PL2718257T3 (pl) | 2011-06-08 | 2018-04-30 | Biogen Ma Inc. | Sposób przygotowywania dimetylofumaranu krystalicznego o wysokiej czystości |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
KR102105217B1 (ko) | 2012-02-07 | 2020-06-01 | 바이오젠 엠에이 인코포레이티드 | 다이메틸 푸마레이트를 함유하는 약학 조성물 |
US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
EP2692343A1 (fr) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Polythérapie pour le traitement de la sclérose en plaques |
US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
US20140056973A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug |
UA119032C2 (uk) * | 2012-10-02 | 2019-04-25 | Женеро Са | Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w |
US20140179779A1 (en) | 2012-12-21 | 2014-06-26 | Biogen Idec Ma Inc. | Deuterium Substituted Fumarate Derivatives |
EP3366668B1 (fr) | 2013-03-14 | 2023-06-21 | Alkermes Pharma Ireland Limited | Promédicaments de fumarates et leur utilisation pour le traitement de diverses maladies |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
JP2016534133A (ja) | 2013-09-06 | 2016-11-04 | ゼノポート,インコーポレイティド | (n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用 |
WO2015105757A1 (fr) * | 2014-01-07 | 2015-07-16 | Biogen Ma Inc. | Fumarate de diméthyle pour traiter une sclérose en plaques |
EP3110793B1 (fr) | 2014-02-24 | 2019-08-21 | Alkermes Pharma Ireland Limited | Sulfonamide et promédicaments de fumarates de sulfinamide et leur utilisation dans le traitement de diverses maladies |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
CA3050086A1 (fr) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Systemes de depot de glatiramere pour le traitement de formes progressives de sclerose en plaques |
US11382889B2 (en) * | 2018-04-19 | 2022-07-12 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | NRF2 activators for the prevention and/or treatment of axonal degeneration |
US11446055B1 (en) | 2018-10-18 | 2022-09-20 | Lumoptik, Inc. | Light assisted needle placement system and method |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
CA2343094A1 (fr) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Proteines de fusion a interferon beta et leurs utilisations |
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
DE14172398T1 (de) | 2004-10-08 | 2015-01-08 | Forward Pharma A/S | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
US20080227847A1 (en) * | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
SI2139467T1 (sl) | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Zaščita živčevja pri demielinizacijskih obolenjih |
US20090104142A1 (en) * | 2007-10-17 | 2009-04-23 | Txcell | Compositions for treating multiple sclerosis |
-
2011
- 2011-02-11 EP EP11742896.1A patent/EP2533634B1/fr not_active Revoked
- 2011-02-11 EP EP15184650.8A patent/EP2982371A1/fr not_active Withdrawn
- 2011-02-11 ME MEP-2015-212A patent/ME02317B/me unknown
- 2011-02-11 ES ES11742896.1T patent/ES2555279T3/es active Active
- 2011-02-11 DK DK11742896.1T patent/DK2533634T3/en active
- 2011-02-11 WO PCT/US2011/024594 patent/WO2011100589A1/fr active Application Filing
- 2011-02-11 PL PL11742896T patent/PL2533634T3/pl unknown
- 2011-02-11 PT PT117428961T patent/PT2533634E/pt unknown
- 2011-02-11 HU HUE11742896A patent/HUE025878T2/en unknown
- 2011-02-11 RS RS20160028A patent/RS54551B1/en unknown
- 2011-02-11 SI SI201130693T patent/SI2533634T1/sl unknown
-
2013
- 2013-03-25 US US13/850,240 patent/US20130287732A1/en not_active Abandoned
- 2013-05-30 HK HK13106428.4A patent/HK1179116A1/xx not_active IP Right Cessation
-
2015
- 2015-12-08 HR HRP20151350TT patent/HRP20151350T1/hr unknown
-
2016
- 2016-01-15 SM SM201600014T patent/SMT201600014B/it unknown
- 2016-03-01 US US15/057,836 patent/US20160250172A1/en not_active Abandoned
-
2017
- 2017-07-07 US US15/644,029 patent/US20180021288A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL2533634T3 (pl) | 2016-04-29 |
EP2533634A4 (fr) | 2013-07-10 |
EP2533634A1 (fr) | 2012-12-19 |
EP2533634B1 (fr) | 2015-10-21 |
US20130287732A1 (en) | 2013-10-31 |
HUE025878T2 (en) | 2016-05-30 |
SI2533634T1 (sl) | 2016-01-29 |
WO2011100589A1 (fr) | 2011-08-18 |
PT2533634E (pt) | 2015-12-28 |
RS54551B1 (en) | 2016-06-30 |
EP2982371A1 (fr) | 2016-02-10 |
SMT201600014B (fr) | 2016-02-25 |
HRP20151350T1 (hr) | 2016-01-01 |
DK2533634T3 (en) | 2016-01-25 |
US20160250172A1 (en) | 2016-09-01 |
HK1179116A1 (en) | 2013-09-27 |
US20180021288A1 (en) | 2018-01-25 |
ME02317B (me) | 2016-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2555279T3 (es) | Neuroprotección en enfermedades desmielinizantes | |
ES2599227T3 (es) | Neuroprotección en enfermedades desmielinizantes | |
US11224584B2 (en) | Sleep apnea treatment | |
ES2859761T3 (es) | Pautas posológicas para el tratamiento de enfermedad de Pompe | |
ES2460617T3 (es) | Combinación de pilocarpina y tiamazol para tratar la enfermedad de Charcot-Marie-Tooth y los trastornos relacionados | |
JP2014521658A (ja) | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 | |
US11918551B2 (en) | Methods of treating seizure disorders and Prader-Willi syndrome | |
AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
PT2763690E (pt) | Lixisenatido para utilização no tratamento de estenose e/ou obstrução no sistema ductal pancreático | |
ES2655291T5 (es) | Uso de cladribina para tratar neuromielitis óptica | |
JP2017533967A (ja) | システアミン組成物を用いるハンチントン病の処置方法 | |
JP4672257B2 (ja) | エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 | |
US8642566B2 (en) | Therapeutic approaches for treating neuroinflammatory conditions | |
ES2198948T3 (es) | Usos de antagonistas de la substancia p para el tratamiento del sindrome de la fatiga cronica y/o de la fibromialgia. | |
KR20070012522A (ko) | 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방 | |
WO2023066330A1 (fr) | Utilisation d'édaravone dans le traitement d'un trouble du spectre de l'autisme | |
ES2528361T3 (es) | Agente antitumoral | |
CN113350488B (zh) | 口服降糖肽ohp在制备抗神经退行性疾病药物方面的应用 | |
US20230181498A1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
US20220211647A1 (en) | Compositions and methods for potentiating derivatives of 4-aminophenols | |
UA146735U (uk) | Фармацевтичний препарат для лікування болю та запалення | |
CN112153967A (zh) | 治疗脱髓鞘的组合物和方法 | |
JP2013018729A (ja) | アルツハイマー病治療剤の作用増強経口用剤 | |
TW201318636A (zh) | 用於治療膽道狹窄或/及阻塞之glp-1促效劑 |